血吸虫病候选疫苗临床研究进展

doi:10.12140/j.issn.1000-7423.2022.04.015

中国寄生虫学与寄生虫病杂志 ›› 2022, Vol. 40 ›› Issue (4): 511-515.doi: 10.12140/j.issn.1000-7423.2022.04.015

血吸虫病候选疫苗临床研究进展

陈兵¹(), 张国莉², 张高红¹^,^*()

1.昆明学院医学院,昆明 650214
2.昆明医科大学药学院,昆明 650500

收稿日期:2021-12-27 修回日期:2022-01-20 出版日期:2022-08-30 发布日期:2022-09-07
通讯作者: 张高红
作者简介:陈兵（1982-）,男,博士,从事寄生适应性进化与寄生虫病防治研究。E-mail： chenbing0318@126.com
基金资助:
云南省教育厅科学研究基金项目(2021J0711);国家自然科学基金面上项目(81860486)

Research progress on clinical trials of schistosomiasis vaccine candidates

CHEN Bing¹(), ZHANG Guo-li², ZHANG Gao-hong¹^,^*()

1. School of Medicine, Kunming University, Kunming 650214, China
2. School of Pharmaceutical Sciences, Kunming Medical University, Kunming 650500, China

Received:2021-12-27 Revised:2022-01-20 Online:2022-08-30 Published:2022-09-07
Contact: ZHANG Gao-hong
Supported by:
Scientific Research Fund Project of Yunnan Education Department(2021J0711);National Natural Science Foundation of China(81860486)

摘要/Abstract

摘要：

血吸虫病是由血吸虫寄生而引起的人兽共患寄生虫病,严重危害人类健康,影响社会经济发展。血吸虫病疫苗一直备受关注,有助于降低对吡喹酮的过度依赖,推进控制和消除血吸虫病目标的实现。目前虽然尚无商业化的血吸虫病疫苗,但谷胱甘肽S-转移酶、脂肪酸结合蛋白、四跨膜蛋白-2和钙蛋白酶大亚基等4种候选疫苗已进入不同阶段的人体临床试验。本文对4种血吸虫病候选疫苗的临床研究进展、面临的挑战进行综述,以期为我国血吸虫病疫苗与其他蠕虫病疫苗的研发提供线索和借鉴。

关键词: 血吸虫病, 疫苗, 抗原, 人体临床试验

Abstract:

Schistosomiasis is a wide-spread parasitic zoonosis caused by Schistosoma, which seriously harms human health and affects socioeconomic development worldwide. Schistosomiasis vaccines have attracted much attention as they will contribute not only to reducing the over-reliance on praziquantel for the treatment of this disease but also to achieving the goal of disease control and elimination. There have been no schistosomiasis vaccines available until now; however, four schistosomiasis vaccine candidates, glutathione S-transferase, fatty acid binding protein, tetraspanin-2 and calpain, have entered human clinical trials. This paper reviewed the clinical research progress and challenges of the four schistosomiasis vaccine candidates to provide insights into developing vaccines for schistosomiasis and other helminthiases in China.

Key words: Schistosomiasis, Vaccine, Antigen, Human clinical trial

中图分类号:

R532.21

陈兵, 张国莉, 张高红. 血吸虫病候选疫苗临床研究进展[J]. 中国寄生虫学与寄生虫病杂志, 2022, 40(4): 511-515.

CHEN Bing, ZHANG Guo-li, ZHANG Gao-hong. Research progress on clinical trials of schistosomiasis vaccine candidates[J]. Chinese Journal of Parasitology and Parasitic Diseases, 2022, 40(4): 511-515.

图/表 1

参考文献 29

[1]	World Health Organization. Schistosomiasis: key facts[EB/OL]. (2021-11-18)[2021-12-10]. https://www.who.int/news-room/fact-sheets/detail/schistosomiasis.
[2]	McManus DP, Dunne DW, Sacko M, et al. Schistosomiasis[J]. Nat Rev Dis Primers, 2018, 4(1): 13. doi: 10.1038/s41572-018-0013-8 pmid: 30093684
[3]	Colley DG, Andros TS, Campbell CH Jr. Schistosomiasis is more prevalent than previously thought: what does it mean for public health goals, policies, strategies, guidelines and intervention programs?[J]. Infect Dis Poverty, 2017, 6: 63. doi: 10.1186/s40249-017-0275-5
[4]	Liang YS. Studies on resistance of Schistosoma to praziquantel in China[J]. Chin Trop Med, 2019, 19(7): 603-607. (in Chinese)
	( 梁幼生. 我国血吸虫对吡喹酮抗药性研究之概要[J]. 中国热带医学, 2019, 19(7): 603-607.)
[5]	Cohen J. Unfilled vials[J]. Science, 2016, 351(6268): 16-19. doi: 10.1126/science.351.6268.16 pmid: 26721985
[6]	Stylianou A, Hadjichrysanthou C, Truscott JE, et al. Developing a mathematical model for the evaluation of the potential impact of a partially efficacious vaccine on the transmission dynamics of Schistosoma mansoni in human communities[J]. Parasit Vectors, 2017, 10(1): 294. doi: 10.1186/s13071-017-2227-0 pmid: 28623957
[7]	Colley DG, Secor WE. Immunology of human schistosomiasis[J]. Parasite Immunol, 2014, 36(8): 347-357. doi: 10.1111/pim.12087 pmid: 25142505
[8]	Fonseca CT, Oliveira SC, Alves CC. Eliminating schistosomes through vaccination: what are the best immune weapons?[J]. Front Immunol, 2015, 6: 95.
[9]	Wang SP, Chen XC, Gao DM. Research progress on schistosome vaccine and prospect of its application in China[J]. Chin J Parasitol Parasit Dis, 2009, 27(5): 402-411. (in Chinese)
	( 汪世平, 陈秀春, 高冬梅. 我国血吸虫疫苗研究进展及应用前景[J]. 中国寄生虫学与寄生虫病杂志, 2009, 27(5): 402-411.)
[10]	Molehin AJ. Schistosomiasis vaccine development: update on human clinical trials[J]. J Biomed Sci, 2020, 27(1): 28. doi: 10.1186/s12929-020-0621-y
[11]	McManus DP. Recent progress in the development of liver fluke and blood fluke vaccines[J]. Vaccines, 2020, 8(3): 553. doi: 10.3390/vaccines8030553
[12]	Torres-Rivera A, Landa A. Glutathione transferases from parasites: a biochemical view[J]. Acta Trop, 2008, 105(2): 99-112. pmid: 17897613
[13]	Capron A, Riveau G, Capron M, et al. Schistosomes: the road from host-parasite interactions to vaccines in clinical trials[J]. Trends Parasitol, 2005, 21(3): 143-149. pmid: 15734662
[14]	Boulanger D, Warter A, Sellin B, et al. Vaccine potential of a recombinant glutathione S-transferase cloned from Schistosoma haematobium in primates experimentally infected with an homologous challenge[J]. Vaccine, 1999, 17(4): 319-326. pmid: 9987169
[15]	Riveau G, Deplanque D, Remoué F, et al. Safety and immunogenicity of rSh28GST antigen in humans: phase 1 randomized clinical study of a vaccine candidate against urinary schistosomiasis[J]. PLoS Negl Trop Dis, 2012, 6(7): e1704. doi: 10.1371/journal.pntd.0001704
[16]	Riveau G, Schacht AM, Dompnier JP, et al. Safety and efficacy of the rSh28GST urinary schistosomiasis vaccine: a phase 3 randomized, controlled trial in Senegalese children[J]. PLoS Negl Trop Dis, 2018, 12(12): e0006968. doi: 10.1371/journal.pntd.0006968
[17]	Chen B, Wen JF. Progress of research on parasitic adaptability of schistosome and its application value[J]. Chin J Schisto Control, 2014, 26(1): 84-89. (in Chinese)
	( 陈兵, 文建凡. 血吸虫的寄生适应性研究及其应用价值[J]. 中国血吸虫病防治杂志, 2014, 26(1): 84-89.)
[18]	Santini-Oliveira M, Coler RN, Parra J, et al. Schistosomiasis vaccine candidate Sm14/GLA-SE: phase 1 safety and immunogenicity clinical trial in healthy, male adults[J]. Vaccine, 2016, 34(4): 586-594. doi: S0264-410X(15)01442-5 pmid: 26571311
[19]	Tendler M, Almeida MS, Vilar MM, et al. Current status of the Sm14/GLA-SE schistosomiasis vaccine: overcoming barriers and paradigms towards the first anti-parasitic human(Itarian) vaccine[J]. Trop Med Infect Dis, 2018, 3(4): 121.
[20]	Tran MH, Pearson MS, Bethony JM, et al. Tetraspanins on the surface of Schistosoma mansoni are protective antigens against schistosomiasis[J]. Nat Med, 2006, 12(7): 835-840. pmid: 16783371
[21]	Kifle DW, Chaiyadet S, Waardenberg AJ, et al. Uptake of Schistosoma mansoni extracellular vesicles by human endothelial and monocytic cell lines and impact on vascular endothelial cell gene expression[J]. Int J Parasitol, 2020, 50(9): 685-696. doi: 10.1016/j.ijpara.2020.05.005
[22]	Keitel WA, Potter GE, Diemert D, et al. A phase 1 study of the safety, reactogenicity, and immunogenicity of a Schistosoma mansoni vaccine with or without glucopyranosyl lipid A aqueous formulation (GLA-AF) in healthy adults from a non-endemic area[J]. Vaccine, 2019, 37(43): 6500-6509. doi: S0264-410X(19)31151-X pmid: 31515141
[23]	Siddiqui AA, Siddiqui SZ. Sm-p80-based schistosomiasis vaccine: preparation for human clinical trials[J]. Trends Parasitol, 2017, 33(3): 194-201. doi: S1471-4922(16)30193-3 pmid: 27865740
[24]	Zhang WD, Molehin AJ, Rojo JU, et al. Sm-p80-based schistosomiasis vaccine: double-blind preclinical trial in baboons demonstrates comprehensive prophylactic and parasite transmission-blocking efficacy[J]. Ann N Y Acad Sci, 2018, 1425(1): 38-51. doi: 10.1111/nyas.13942
[25]	Siddiqui AJ, Molehin AJ, Zhang WD, et al. Sm-p80-based vaccine trial in baboons: efficacy when mimicking natural conditions of chronic disease, praziquantel therapy, immunization, and Schistosoma mansoni re-encounter[J]. Ann N Y Acad Sci, 2018, 1425(1): 19-37. doi: 10.1111/nyas.13866
[26]	Ahmad G, Zhang WD, Torben W, et al. Preclinical prophylactic efficacy testing of Sm-p80-based vaccine in a nonhuman primate model of Schistosoma mansoni infection and immunoglobulin G and E responses to Sm-p80 in human serum samples from an area where schistosomiasis is endemic[J]. J Infect Dis, 2011, 204(9): 1437-1449. doi: 10.1093/infdis/jir545 pmid: 21921206
[27]	Langenberg MCC, Hoogerwerf MA, Koopman JPR, et al. A controlled human Schistosoma mansoni infection model to advance novel drugs, vaccines and diagnostics[J]. Nat Med, 2020, 26(3): 326-332. doi: 10.1038/s41591-020-0759-x pmid: 32066978
[28]	Zhang LL, Xu XD, Pan WQ. An investigation of polymorphism in the tetraspanin-2 gene of Schistosoma japonicum[J]. Int J Med Parasit Dis, 2011, 38(5): 257-260. (in Chinese)
	( 张丽丽, 徐新东, 潘卫庆. 日本血吸虫被膜蛋白Sj-TSP2基因序列多态性分析[J]. 国际医学寄生虫病杂志, 2011, 38(5): 257-260.)
[29]	Molehin AJ, Gray SA, Turner C, et al. Process development of sj-p80: a low-cost transmission-blocking veterinary vaccine for asiatic schistosomiasis[J]. Front Immunol, 2021, 11: 578715. doi: 10.3389/fimmu.2020.578715

候选疫苗	抗原	虫种	临床试验阶段	临床（前）试验结果
rSh28GST/Alhydrogel	GST	埃及血吸虫	Ⅰ、Ⅱ、Ⅲ期完成	赤猴组织中虫卵减少50%,随尿液排除虫卵减少80%。Ⅲ期试验中,保护效果未达到预期水平。成人及儿童耐受性良好
Sm14/GLA-SE	FABP	曼氏血吸虫	Ⅰa、Ⅰb、Ⅱa、Ⅱb期完成	完成3次接种后,92%的受试者产生特异性抗体并可持续1年,同时诱导Th1和Th2型免疫应答。成人耐受性良好
Sm-TSP-2/Alhydrogel	TSP-2	曼氏血吸虫	Ⅰa、Ⅰb期完成,Ⅱ期开始	IgG抗体水平显著增长并与疫苗剂量、佐剂选择相关。成人耐受性良好
Sm-p80/GLA-SE	Calpain	曼氏血吸虫	Ⅰ期开始	狒狒免疫后,雌虫减虫率为93%,减卵率为90%,剩余虫卵孵化率降低80%。无IgE抗体应答

血吸虫病候选疫苗临床研究进展

Research progress on clinical trials of schistosomiasis vaccine candidates

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

图/表 1

参考文献 29

相关文章 15

编辑推荐

Metrics

本文评价

[1]	姜文静, 孟雅莉, 赵利娜, 王春苗, 张晓磊. 刚地弓形虫棒状体蛋白18和膜表面抗原30复合核酸疫苗对小鼠的免疫保护作用[J]. 中国寄生虫学与寄生虫病杂志, 2023, 41(5): 532-538.
[2]	谭潇, 朱琪, 刘众齐, 李佳, 彭丁晋. 日本血吸虫Sj26gst mRNA候选疫苗的免疫原性研究[J]. 中国寄生虫学与寄生虫病杂志, 2023, 41(5): 546-551.
[3]	芦星, 王水怡, 陈林军, 刘明明, 刘雨桐, 朱慧茹, 姜冰冰, 杜少磊, 巴音查汗, 刘丹丹, 张伟. 马泰勒虫棒状体颈部蛋白5基因的克隆与原核表达[J]. 中国寄生虫学与寄生虫病杂志, 2023, 41(4): 497-501.
[4]	叶井明, 何威, 刘慧媛, 鱼潇, 罗波, 刘美辰, 周必英. 猪囊尾蚴排泄分泌抗原TPx对仔猪树突状细胞活化的影响[J]. 中国寄生虫学与寄生虫病杂志, 2023, 41(3): 286-293.
[5]	李婕, 文雨松, 李召军. 我国旅游开发对血吸虫病防治的影响[J]. 中国寄生虫学与寄生虫病杂志, 2023, 41(3): 355-360.
[6]	焦红杰, 齐文静, 郭刚, 包建玲, 吴川川, 宋传龙, 李军, 张文宝, 严媚. 细粒棘球蚴抗原B对小鼠巨噬细胞RAW264.7的极化作用[J]. 中国寄生虫学与寄生虫病杂志, 2023, 41(1): 23-28.
[7]	陈琳, 朱继峰, 邱竞帆, 徐志鹏, 张东辉, 陈璐, 何健, 李伟, 杨坤, 季旻珺. 寓全健康理念于血吸虫病防控虚拟仿真项目建设[J]. 中国寄生虫学与寄生虫病杂志, 2023, 41(1): 81-84.
[8]	吴晓莹, 胡媛, 曹建平. 寄生虫病表位疫苗研究进展[J]. 中国寄生虫学与寄生虫病杂志, 2023, 41(1): 98-102.
[9]	邹伟浩, 吴蔚玲, 廖远鹏, 陈敏, 彭鸿娟. 刚地弓形虫抗缓殖子期抗原1单克隆抗体的制备与应用[J]. 中国寄生虫学与寄生虫病杂志, 2022, 40(5): 587-593.
[10]	李润花, 殷国荣. 刚地弓形虫病多表位疫苗的研究进展[J]. 中国寄生虫学与寄生虫病杂志, 2022, 40(5): 661-667.
[11]	冯家鑫, 公衍峰, 罗卓韦, 汪伟, 曹淳力, 许静, 李石柱. 我国血吸虫病防治策略的科学基础与“十四五”展望[J]. 中国寄生虫学与寄生虫病杂志, 2022, 40(4): 428-435.
[12]	高元, 胡媛, 曹建平. 免疫细胞对血吸虫病肝纤维化作用的研究进展[J]. 中国寄生虫学与寄生虫病杂志, 2022, 40(1): 88-93.
[13]	于嘉利, 刘蕾, 杨博, 楚瑞林, 孙毅凡, 刘耀宝, 程洋. 重组卵形疟原虫裂殖子表面蛋白1 N端的抗原性及免疫原性分析[J]. 中国寄生虫学与寄生虫病杂志, 2021, 39(6): 746-752.
[14]	郭苏影, 祝红庆, 曹淳力, 邓王平, 鲍子平, 贾铁武, 李银龙, 吕超, 秦志强, 张利娟, 冯婷, 杨帆, 吕山, 许静, 李石柱. 2020年长江中下游地区洪涝灾害后血吸虫病传播风险评估[J]. 中国寄生虫学与寄生虫病杂志, 2021, 39(6): 753-758.
[15]	施亮, 熊春蓉, 刘毛毛, 魏秀参, 张键锋, 王鑫瑶, 王涛, 杭德荣, 羊海涛, 杨坤. 基于深度学习技术的湖北钉螺视觉智能识别模型效能评价[J]. 中国寄生虫学与寄生虫病杂志, 2021, 39(6): 764-770.